News
HRTX
2.645
-2.40%
-0.065
Heron Therapeutics: Zynrelef Potentially Eases Shareholder Pain
Heron Therapeutics has received approval for its supplemental New Drug Application for Zynrelef. The drug is used in more surgical procedures. The company has partnered with Crosslink Life Sciences to promote the drug in 2024. HRTX is expected to see sales growth in 2024, with a vial access needle form of the drug being approved.
Seeking Alpha · 2d ago
Weekly Report: what happened at HRTX last week (0408-0412)?
Weekly Report · 4d ago
Needham Reiterates Buy on Heron Therapeutics, Maintains $5 Price Target
Benzinga · 04/11 10:02
Heron Therapeutics: A Strong Buy Based on Strategic Positioning and Growth Potential
TipRanks · 04/11 09:55
Commit To Buy Heron Therapeutics At $2, Earn 22.4% Annualized Using Options
NASDAQ · 04/10 17:02
Weekly Report: what happened at HRTX last week (0401-0405)?
Weekly Report · 04/08 11:08
Weekly Report: what happened at HRTX last week (0325-0329)?
Weekly Report · 04/01 11:06
Weekly Report: what happened at HRTX last week (0318-0322)?
Weekly Report · 03/25 11:08
Heron Therapeutics Announces New Principal Accounting Officer
TipRanks · 03/21 20:42
Weekly Report: what happened at HRTX last week (0311-0315)?
Weekly Report · 03/18 11:07
Why Is Postoperative Pain Focused Heron Therapeutics Stock Trading Higher On Wednesday?
Heron Therapeutics Inc (NASDAQ:HRTX) reported a fourth-quarter 2023 EPS of $0.07. Sales increased 14% Y/Y to $34.23 million. Needham maintains its Buy rating on the company's stock.
Benzinga · 03/13 18:41
12 Health Care Stocks Moving In Wednesday's Intraday Session
Heron Therapeutics shares rose 35.4% to $3.19 during Wednesday's regular session. The company's, Q4 earnings came out yesterday. Trxade Health (NASDAQ:MEDS) shares fell 22.6% during the session. NuCana stock rose 34.32% and Cardiff Oncology shares increased by 27.9%.
Benzinga · 03/13 17:31
Why Clover Health Investments Shares Are Trading Higher By 11%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Clover Health Investments, Corp. Shares jumped 11.2% to $0.8537 on Wednesday. The company reported better-than-expected fourth-quarter revenue results. Gaxos.ai shares jumped 128.9% after the company acquired rights to use certain AI-enabled technology from Ultiself. Veritone, Inc. And The Beauty Health Company also gained.
Benzinga · 03/13 17:18
HRTX, LUNA and ARQ among mid-day movers
On the Move HRTX, LUNA and ARQ among mid-day movers. Gaxos.AI and MicroCloud Hologram are among the Gainers. 1847 Holdings and Luna Innovations were among the losers in SA's list of companies.
Seeking Alpha · 03/13 17:18
Heron Therapeutics Soars After 4Q Earnings Beat
Heron Therapeutics' stock was up 27% after its fourth-quarter earnings beat expectations. Shares of the San Diego-based biotechnology company rose to $3.01 in morning trading. The stock is up more than 20% over the past 12 months. Heron narrowed its losses and beat expectations in the fourth quarter.
Dow Jones · 03/13 15:00
Solid Biosciences, Cue Biopharma, Annexon among healthcare movers
Solid Biosciences, Cue Biopharma, Annexon among healthcare movers. S&P 500 Health Care Sector +0.01% to 1710.78. Pharmaceuticals, Biotechnology & Life Science contributes 0.14% to index is -0.12%.
Seeking Alpha · 03/13 14:00
Northland Securities Keeps Their Buy Rating on Heron Therapeutics (HRTX)
TipRanks · 03/13 12:56
Heron Therapeutics Price Target Raised to $5.00/Share From $4.00 by Needham
Dow Jones · 03/13 10:37
Heron Therapeutics Is Maintained at Buy by Needham
Dow Jones · 03/13 10:37
Needham Maintains Buy on Heron Therapeutics, Raises Price Target to $5
Benzinga · 03/13 10:28
More
Webull provides a variety of real-time HRTX stock news. You can receive the latest news about Heron Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About HRTX
Heron Therapeutics, Inc. is a commercial-stage biotechnology company. The Company commercializes a portfolio of products to care for acute care and oncology patients. Its oncology care product portfolio includes SUSTOL and CINVANTI. SUSTOL is used for the prevention of acute and delayed nausea and vomiting associated with both moderately emetogenic chemotherapy (MEC), and anthracycline and cyclophosphamide (AC) combination chemotherapy regimens. CINVANTI is an intravenous (IV) formulation of aprepitant, a substance P/neurokinin-1 (NK1) receptor antagonist. Its acute care product portfolio includes ZYNRELEF and APONVIE. HTX- ZYNRELEF is a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam. APONVIE is the IV formulation of a NK1 receptor antagonist indicated for postoperative nausea and vomiting (PONV). Its products are distributed in the United States.